Linezolid Hetero

Linezolid

Susceptible gm +ve infections in adults ≥12 yr. Community-acquired pneumonia caused by penicillin-sensitive Strep pneumoniae including cases w/ concurrent bacteraemia, or methicillin-sensitive Staph aureus. Nosocomial pneumonia caused by Staph aureus (methicillin-sensitive & -resistant strains) or penicillin-sensitive Strep pneumoniae. Uncomplicated skin & skin structure infections caused by methicillin-sensitive Staph aureus or Strep pyogenes. Complicated skin & skin structure infections, caused by Staph aureus (methicillin-sensitive & -resistant strains), Strep pyogenes or Strep agalactiae. Vancomycin-resistant Enterococcus faecium including cases w/ concurrent bacteraemia.

Community-acquired & nosocomial pneumonia, & complicated skin & soft tissue infections Adult & adolescent ≥12 yr 600 mg every 12 hr for 10-14 days. Uncomplicated skin & soft tissue infections Adult 400 mg every 12 hr for 10-14 days. Adolescent 600 mg every 12 hr for 10-14 days. Vancomycin-resistant enterococcus infections Adult & adolescent ≥12 yr 600 mg every 12 hr for 10-28 days.

May be taken with or without food.

Hypersensitivity. Concomitant use w/in 2 wk of taking MAOIs. Patients w/ uncontrolled HTN, pheochromocytoma, thyrotoxicosis &/or patients taking directly- & indirectly-acting sympathomimetic agents (eg, pseudoephedrine, phenylpropanolamine), vasopressive agents (eg, epinephrine, norepinephrine), dopaminergic agents (eg, dopamine, dobutamine). Patients w/ carcinoid syndrome &/or patients taking SSRIs, TCAs, serotonin 5-HT1 receptor agonists (triptans), meperidine or buspirone.

Not for gm -ve infections. Pseudomembranous colitis. Consider Clostridium difficile-associated diarrhea in all patients who present w/ diarrhea following antibiotic use; careful medical history is necessary. Consider discontinuation in patients who developed or have worsening myelosuppression; monitor complete blood counts wkly, particularly those treated for >2 wk, w/ pre-existing myelosuppression, receiving concomitant drugs that produce bone marrow suppression, or w/ chronic infection who received previous or concomitant antibitotic therapy. Lactic acidosis. Peripheral & optic neuropathy, primarily in patients treated for >28 days. Convulsions; history or risk factors for seizures. Serotonin syndrome associated w/ co-administration w/ serotonergic agents, including antidepressants eg, SSRIs. Patients at high risk for life-threatening systemic infections eg, infections related to central venous catheters in ICU; not for catheter-related bloodstream infections. Hepatic & severe renal impairment (ie, CrCl <30 mL/min). Pregnancy & lactation. Not recommended in childn.

Diarrhoea, headache, nausea, vomiting, insomnia, constipation, rash, dizziness, fever.

Decreased C_max & AUC by rifampicin. Potential interaction w/ adrenergic & serotonergic agents, & dextromethorphan. Avoid large amounts of food or beverage w/ high tyramine content (eg, mature cheese, yeast extr, undistilled alcoholic beverages, fermented soya bean products).

Other Antibiotics

J01XX08 - linezolid ; Belongs to the class of other antibacterials. Used in the systemic treatment of infections.